ASH 2020

Complete Coverage

Prognostic Biomarker Testing in CLL/SLL Remains Low

Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.

TOURMALINE-MM2: Ixazomib Plus Lenalidomide and Dexamethasone for Newly Diagnosed MM

A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.

Prognostic Biomarker Testing in CLL/SLL Remains Low

Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.

Liso-Cel Plus Ibrutinib Demonstrated Efficacy in R/R CLL/SLL

A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.

Umbralisib Plus Ublituximab Improved PFS vs Chemoimmunotherapy in CLL

The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.

Promising Efficacy Seen With LOXO-305 in R/R CLL/SLL

LOXO-305 treatment of heavily pretreated CLL/SLL resulted in durable, high response rates in a phase 1/2 trial.

Older Patients With NHL Are at Higher Risk for Hospitalization vs Non-Cancer Controls

The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).

Sociodemographic Characteristics a Strong Factor in EOL Healthcare Utilization in Acute Myeloid Leukemia

Researchers sought to determine how and which factors contribute to healthcare utilization by patients with AML at the end of life.

Cytarabine in Young Adults With AML: Subcutaneous Injection Noninferior to IV Infusion

Open-label, randomized clinical trial sought to determine noninferiority of subcutaneous and IV infusion cytarabine in young adults with AML.

Survival Improving for Patients With Acute Lymphoblastic Leukemia Who Experience Relapse Following HSCT

Researchers identify factors that influence relapse after HSCT in patients with acute lymphoblastic leukemia.

Combination Therapies With Venetoclax Preserved Health Status, QOL in Older Patients With AML

Comparison of results from 2 phase 3 studies of combination therapies are presented at ASH 2020.

Venetoclax-Azacitidine Combination Efficacious for the Treatment of Older Patients With Higher-Risk Myelodysplastic Syndrome

Combination therapy positively influenced overall survival rates, dyspnea, and fatigue through 48 weeks in this patient population.

Interim Analysis Shows Benefit of First-Line Axi-Cel in High-Risk LBCL

Axi-cel demonstrated significant clinical benefit as a first-line treatment for patients with high-risk large B-cell lymphoma.

Men at Increased Risk for Mortality Following Allogeneic Hematopoietic Stem Cell Transplant

A retrospective analysis compared survival rates after allogeneic hematopoietic stem cell transplantation in men with those of women.

Large Disparities in End-of-Life Care Observed Between Solid Tumors and Hematologic Malignancies

An analysis of data from SEER-Medicare database compared end-of-life care, including hospitalizations and use of hospice, between patients with solid tumors and hematologic malignancies.

Nearly Half of Multiple Myeloma Deaths Occur During Hospitalization

Researchers present data regarding end-of-life care management in patients with multiple myeloma.

Bispecific CAR-T Therapy Found to Have Promising Efficacy in Older Patients With R/R B-Cell NHL

The bispecific CAR-T therapy targets CD20 and CD19.

Response Rates in Phase 1 Studies of Hematologic Malignancies Improved Over Time

Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.

Real-World Data: Ibrutinib Improves Outcomes vs Chemoimmunotherapy in CLL

Ibrutinib was associated with a longer duration until second-line treatment, regardless of risk status, compared with CIT among patients with CLL.

Hospitalization Burden of Patients with Multiple Myeloma

Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.